# RAPT Therapeutics, Inc. — merger [completed]
Source: SEC API (secapi.ai) · situation sit_54d04b344cef996e8d0c · retrieved 2026-08-11T16:10:48.137Z

## Overview
RAPT Therapeutics, Inc. is a pharmaceutical company developing therapeutic treatments.

Redrose Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline LLC (itself an indirect subsidiary of GSK plc), completed a tender offer to acquire all issued and outstanding shares of RAPT Therapeutics, Inc. for $58.00 per share in cash. As of the expiration time on March 2, 2026 at 11:59 P.M. Eastern Time, 30,137,567 shares (approximately 93.36% of outstanding shares) had been validly tendered. The merger between Purchaser and the Company is expected to close on March 3, 2026, with the Company continuing as a direct wholly-owned subsidiary of Parent, and the shares will be delisted from the Global Select Stock Market.

## Terms
- Counterparty: GlaxoSmithKline LLC (Parent) / Redrose Acquisition Co. (Purchaser) · Consideration: cash · Premium: 65.0% · Stake: 93.36% · Price/share: $58

## Key dates
- Expiry 2026-03-02

## Timeline
- 2026-02-02 · SC 14D9 (0001193125-26-032788): SC 14D9 - RAPT Therapeutics, Inc. — *RAPT Therapeutics, Inc. is a biopharmaceutical company developing ozureprubart (formerly RPT904), a lead product candidate for food allergy and chronic spontaneous urticaria, and pursuing clinical development of early-stage pipeline assets.* GlaxoSmithKline LLC (through subsidiary Redrose Acquisition Co.) launched a tender offer to acquire all outstanding shares of RAPT Therapeutics, Inc. for $58.00 per share in cash, without interest and net to stockholders. The offer, dated February 2, 2026, is governed by a Merger Agreement dated January 19, 2026, under which Purchaser will merge with and into RAPT, with RAPT continuing as a wholly-owned subsidiary of Parent. The transaction is expected to be consummated under Section 251(h) of the Delaware General Corporation Law, which does not require a separate stockholder vote following successful completion of the tender offer. GSK plc (the Ultimate Parent) has guaranteed the obligations of Parent and Purchaser under the Merger Agreement.
  https://www.sec.gov/Archives/edgar/data/1673772/0001193125-26-032788.txt
- 2026-03-03 · SC 14D9/A (0001193125-26-086530): SC 14D9/A - RAPT Therapeutics, Inc. — *RAPT Therapeutics, Inc. is a pharmaceutical company developing therapeutic treatments.* Redrose Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline LLC (itself an indirect subsidiary of GSK plc), completed a tender offer to acquire all issued and outstanding shares of RAPT Therapeutics, Inc. for $58.00 per share in cash. As of the expiration time on March 2, 2026 at 11:59 P.M. Eastern Time, 30,137,567 shares (approximately 93.36% of outstanding shares) had been validly tendered. The merger between Purchaser and the Company is expected to close on March 3, 2026, with the Company continuing as a direct wholly-owned subsidiary of Parent, and the shares will be delisted from the Global Select Stock Market.
  https://www.sec.gov/Archives/edgar/data/1673772/0001193125-26-086530.txt

## Citations
- 0001193125-26-032788 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526032788
- 0001193125-26-086530 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526086530